Infographic created for client from word document.

11. GSK Focused On Minimizing Need For
Cumulative Drug Exposure
Glaxo is the second-largest HIV company, with revenue of about $5.2 billion versus Gilead's $12.9 billion.
Long-life antiretroviral therapy that the HIV infected have to endure has created a need to minimize cumulative
drug exposure. Glaxo wants to develop HIV therapies that meet that need. It believes the potency, safety and resistance
barrier of dolutegravir and the efficacy, safety and tolerability of Johnson & Johnson's (NYSE:JNJ) rilpivirine make
them ideal for a two-drug regimen.